May 15, 2026 · Phase 2 readout
TNGX Phase 2 readout: a negative outcome, -17.3%
On May 15, 2026, TNG462 — Tango Therapeutics, Inc. (Locally Advanced Solid Tumor) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -17.3% in the window around the event. It had already run -7.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$24.87
1d before
$20.56
Event day
$20.56
1d after
$21.08
5d after
Our prediction vs. the result
CatalystAlert called this one up (+5.0% expected); the stock actually moved -17.3%. Model confidence at the time: 60%.
See the full scored track recordPre-catalyst setup
-7.2%
30-day run-up
7649%
30-day volatility
1.8×
volume spike